Niraparib
ATC Code
L01XK02
Niraparib
Definition
An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.
Also known as MK 4827, MK-4827, MK4827, NIRAPARIB — per NCIT
Also identified as
- ATC L01XK02 per RXNORM
- NCIT NCIT:C80059 per NCIT
- SCTID 733733005 per RXNORM
- SCTID 763561009 per RXNORM
- UNII HMC2H89N35 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Fallopian tube neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
| Ovarian cancer | may treat | MEDRT · Public domain (U.S. Government work) |
| Peritoneal neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |